Melasma Treatment Market Size, Share, Industry, Forecast and outlook (2024-2031)

Melasma Treatment Market is Segmented By Type(Epidermal,Dermal, Mixed, Others), By Treatment(Medication, Skin Peels, Laser and light treatment, Others), By Route of Administration(Oral, Topical, Others), By End-User(Hospitals, Dermatology, Homecare, Others), By Distribution Channel(Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031.

Report Overview

Melasma Treatment Market is growing at a CAGR 7.3% during the forecast period (2024-2031).

Melasma is a common pigmentation disorder that causes brown or gray patches to appear on the skin, primarily on the face. It can be found primarily in individuals with light brown skin to darker skin tones, especially in areas with high sun exposure. Women are particularly susceptible to melasma, and it can appear as brown patches on the face, especially the cheeks, nose bridge, and forehead. Sometimes, melasma is extremely difficult to treat. When the patients follow the treatment plan, it usually takes between 3 to 12 months to see results. It may take longer if patients have had melasma for a long time.

As per DataM Intelligence, Melasma Treatment Market study analysis offers an in-depth outlook on the market containing quantitative and qualitative data. It gives an outlook and forecast of the global market based on market segmentation. It also provides global Melasma Treatment Market size, and growth, along with the latest trends, opportunities, and forecast till 2029 for the global market with esteem to major countries such as the United States, Canada, Brazil, Germany, Italy, Spain, United Kingdom, Russia, European countries, United Arab Emirates, Saudi Arabia, South Africa, Japan, China, India, South Korea, Australia, and rest of the countries over the globe.

Among all regions, the North American region is expected to hold the largest share of the global market over the forecast period. Melasma Treatment Market in the United States and Canada produces the utmost share. Whereas the European Melasma Treatment Market is projected to continue its presence globally during the period of 2024-2031.

Market Summary

For more details on this report - Request for Sample

Market Dynamics

Advancement in the treatment of Melasma is expected to drive market growth.

Opsin-3, which activates the melanogenesis-associated transcription factor and other melanogenic enzymes, including tyrosinase and dopachrome tautomerase, has recently been stimulated by visible blue light. Tyrosinase and dopachrome form a protein complex mostly produced in the melanocytes of people with dark skin. As a result, the long-term consequences of visible blue light irradiation in people with darker skin types can cause hyperpigmentation in skin types III and more. As a result, photoprotection with visible light, such as iron oxide sunscreens, is required. Moreover, Cysteamine hydrochloride (ß–mercaptoethylanine hydrochloride) is a breakdown product of the amino acid L-cysteine that occurs naturally in the human body. Cysteamine also acts as a radioprotector, protecting cells from the mutagenesis and other harmful effects of ionizing radiation by scavenging hydroxy radicals directly. Thus, the market is expected to boost in the forecast period from the above statements.

Restraint:

Fewer Side effects of the drugs, low healthcare budgets in underdeveloped countries and many pharmaceutical companies having limited operating income opportunities to research and develop targeted treatments are some factors the market is expected to get hampered in the forecast period.

COVID-19 Impact Analysis

The COVID-19 pandemic has moderately impacted healthcare systems and the market. The pandemic resulted in an increase in the frequency of some anxiety-related diseases and significant decreases in the number. Moreover, it resulted in lower visits to hospitals and dermatology clinics and postponed elective surgery due to the economic downturn, which hampered the market growth. Dermatological disorders such as scabies and venereal diseases, especially related to public health, may cause future problems because of delays in seeking treatment. Various alternatives, such as teledermatology, are developed in light of the ongoing pandemic's uncertainties. Understanding the patterns in dermatological illnesses and the changing health system during the pandemic will aid in the development of future treatments.

Additionally, the pandemic interrupts the supply chain and process. Many companies will vary to other geographic regions to ensure that products remain available and protect their supply chain. Thus, from the above statements, the market got affected, and it is expected to gain traction quickly with the resumption of the economic activities.

Market Segment Analysis

Medication segment is expected to hold the largest market share in melasma treatment market

The medication segment is expected to dominate in 2021. The dermatologist prescribes medication that can decrease the excess pigment in your skin. Most patients receive a prescription for medication that they apply to their skin at home. For instance, Triple combination cream (hydroquinone, tretinoin, and corticosteroid) remains the most effective treatment for melasma and hydroquinone alone. Moreover, Oral tranexamic acid is a promising new treatment for moderate and severe recurrent melasma. Therefore, it has increased the demand for drugs. Thus, the market segment is expected to hold the largest market share in the forecast period from the above statements.

Market Geographical Analysis

North America region holds the largest market share in the global melasma treatment market

In 2021, North America accounted for the highest revenue share. The increasing prevalence of melasma, high adoption of advanced treatment, rising healthcare expenditure in the region, and advancement in Melasma diagnosis are factors the market is expected to boost in the forecast period. For instance, According to the American Academy of Dermatology, only 10% of all cases of melasma occur in males. Females and those who are pregnant are at greater risk of developing melasma. Moreover, recent advancements in optical imaging technology have the potential to increase melasma diagnosis accuracy and impact treatment. Reflectance confocal microscopy (RCM) is a laser scanning microscopy technique that produces greyscale pictures with a sub-micron resolution by deriving contrast from differences in tissue refractive index. Grayscale photographs are usually suitable for assessing tissue structure in general. As a result, RCM was used to image melasma. Thus, the North American region is expected to hold the largest market share in the forecast period from the above statements.

Competitive Landscape

Major key players in the melasma treatment market are Eastman Chemical Company, Azelaic Products B.V., Genericure, Cynosure, LLC, LUTRONIC AUSTRALIA, La Pristine, Galderma Laboratories, Apollo Pharmacy. 

Cynosure, LLC:

Overview:

Cynosure is headquartered out of Westford, MA, United States. It is a developer and manufacturer of a broad array of light-based aesthetic and medical treatment systems. Their products are used to provide a diverse range of treatment applications such as hair removal, skin rejuvenation and scar reduction, and the treatment of vascular lesions.

­Product Portfolio:

ICON: It uses the body’s natural processes. Icon’s advanced laser technology targets unwanted pigment to reveal clear and even skin.